Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales. Continue reading View comments
- Supported exchanges /
- PA /
- SAN.PA
Sanofi SA (SAN PA) stock market data APIs
€100.74
0.7(0.7%)
as of October 29, 2024
Price chart is built with Anychart
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi SA Financial Data Overview
| 100.1 | |
| 100.74 | |
| - | |
| 101.61 | |
| 100.09 | |
| 79.5572-106.14 | |
| 127 270 M | |
| 28.0724 | |
| 1 254 M | |
| 48 445 M | |
| 0.0376 | |
| 0.423 |
Our easy-to-use no-coding solutions help you get the data effortlessly:
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
General: {
Code:
'SAN',
Type:
'Common Stock',
Name:
'Sanofi SA',
Exchange:
'PA',
CurrencyCode:
'EUR',
CurrencyName:
'Euro',
CurrencySymbol:
'€',
CountryName:
'France',
CountryISO:
'FR',
OpenFigi:
NULL,
ISIN:
'FR0000120578',
CIK:
NULL,
EmployerIdNumber:
NULL,
FiscalYearEnd:
'December',
IPODate:
NULL,
InternationalDomestic:
NULL,
Sector:
'Healthcare',
Industry:
'Drug Manufacturers - General',
}
Sanofi SA Fundamental Data is available in our Financial Data APIs
- Net Revenue 48 445 M
- EBITDA 12 503 M
- Earnings Per Share 3.59
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Sanofi SA Earnings via APIs
- Latest Release 2024-10-25
- EPS/Forecast NaN
Get Sanofi SA End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Get Sanofi SA latest news via APIs
Sanofi Deal Jitters Imperil Stock’s Big Rebound
The French drugmaker on Monday announced progress on a deal to sell 50% of its over-the-counter division to Clayton Dubilier & Rice. Continue reading View comments
Do you have any questions?
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
